SEP
AMRX icon

Signature Equity Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Signature Equity Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.4K Sell
4,218
-87
-2% -$1.17K 0.03% 399
2025
Q4 		$54.2K Buy
+4,305
New +$49.3K 0.03% 378

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Signature Equity Partners's AMRX Position: Q1 2026 in Review

Signature Equity Partners reduced its Amneal Pharmaceuticals (AMRX) stake by 2% in Q1 2026, selling an estimated $1.17K and leaving 4,218 shares worth $52.4K. The position accounts for 0.03% of the portfolio, ranked #399.

Signature Equity Partners first reported a position in AMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $54.2K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Signature Equity Partners held 4,218 shares of Amneal Pharmaceuticals worth $52.4K as of Q1 2026.
  • Signature Equity Partners sold 87 Amneal Pharmaceuticals shares in Q1 2026, an estimated $1.17K.
  • Amneal Pharmaceuticals made up 0.03% of Signature Equity Partners's portfolio in Q1 2026, its #399 holding.
  • Signature Equity Partners first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's Amneal Pharmaceuticals position peaked at $54.2K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.